Feds on COVID-19 mRNA vaccine distribution: Pfizer's dry runs predict a 'very doable process' BioNTech, Fosun start COVID-19 vaccine trial to support Chinese approval Sanford Health CEO steps down after sparking controversy for not wearing mask CureVac ties up Wacker to churn out more than 100M doses of mRNA coronavirus vaccine Northwestern publishes open AI that spots COVID-19 in chest X-rays Biopharma roundup—Azar pegs 6.4M Pfizer doses for mid-December Healthcare roundup—Poll finds many adults will wait to get COVID vaccine Mount Sinai, RenalytixAI joint venture gets green light for COVID-19 antibody test How mapping technology and location intelligence will help COVID-19 vaccine distribution Covaxx inks supply deals worth $2.8B in lead-up to coronavirus vaccine midstage trials Ascension earnings bolstered by increased joint venture revenue, COVID-19 relief Johnson & Johnson assures docs and patients its Janssen pharma unit 'Never Stops' Featured Story | By Arlene Weintraub More than 6 million doses of Pfizer's COVID-19 mRNA vaccine could ship in mid-December, Operation Warp Speed officials said. To get the vaccine out quickly to high-risk groups, Pfizer has been running rehearsals at distribution sites around the country, creating "growing confidence" in the rollout, they added. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor BioNTech and Fosun Pharma have begun a phase 2 trial of their COVID-19 vaccine in China. The trial will generate data to support a filing for approval of the vaccine, which is nearing authorization in the West, in China. read more By Tina Reed Longtime Sanford Health President and CEO Kelby Krabbenhoft is stepping down after sparking controversy for refusing to wear a mask. read more By Kyle Blankenship Riding a wave of interest in mRNA-based vaccines, Germany's CureVac is looking to capitalize and rapidly drive manufacturing of its own shot candidate. After announcing a plan to bring more partners on board, CureVac has knotted the first of those deals to the tune of 100 million doses. read more By Conor Hale Researchers at Northwestern University have trained an artificial intelligence algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs, and it’s capable of outperforming a team of specialized readers. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner States will likely receive 6.4 million Pfizer doses by mid-December, Alex Azar said. COVAX has secured hundreds of millions of AstraZeneca doses. Fosun and BioNTech are plotting a phase 2 trial of the German firm's mRNA-based shot. Sinopharm reportedly filed to market its late-stage vaccine. States will have final say over distribution of initial doses. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Conor Hale A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been granted an emergency green light from the FDA. read more By Brian T. Horowitz While vaccine makers have delivered some good news on a potential COVID-19 vaccine, a key challenge will be how to distribute the vaccine effectively. GIS mapping software and location intelligence will play a key role in this effort, experts say. Here's how one Minnesota county has been preparing for COVID-19 vaccine distribution by testing location intelligence technology during this fall’s flu vaccine rollout. read more By Kyle Blankenship While some of the leading players in the race for a COVID-19 vaccine are racing toward the finish line, a range of smaller challengers is still hoping to carve out a market niche in the coming months. One of those, New York's Covaxx, is rolling out its first swath of supply deals—and touting its shot's logistics advantage. read more By Tina Reed St. Louis-based Ascension Health posted $1.2 billion in net income in the first quarter of its fiscal year that ended Sept. 30. read more By Beth Snyder Bulik Johnson & Johnson's Janssen wants patients and doctors to know they can still count on the drugmaker—even during a pandemic. A new corporate campaign from the pharma arm of Johnson & Johnson reassures people that it continues to develop and produce medicines, even as its scientists also work on a COVID-19 vaccine. read more | | Roundtable: Creating Sustainable Change in HCP Engagement Tuesday, December 8 | 11am ET / 8am PT To succeed in today’s environment, biopharmaceutical companies must leverage analytics and adopt innovative approaches to engage HCPs and improve outcomes for their customers and communities. Join us for a roundtable discussion with leading industry innovators to discuss how biopharma manufacturers can successfully increase and improve HCP engagement. Register now. |
| 